Walgreen Boots Alliance (WBA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Walgreen Boots Alliance (WBA)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

12.05

+0.07 (0.58%)

as of Aug 27, 2025, 11:48:28 pm Market Open.

122 watching

COMMENT

Has always been a well regarded drugstore company. Good acquirer. Trading at around 22 X earnings. A lot of pharmacies made good money from photo processing, which is an area that is slowing down. Wal-Mart is getting very aggressively into the pharmacy business.

HOLD

Big pull back on the stock when Wal-Mart announced their new drug plan. Feels the valuations in this sector are high.

TOP PICK

Reported revenues up 16% and same store sales up 9%. Still has more room to grow. Very cheap.

BUY

Like many of the large caps in the US, the stock has not moved a lot. They're adding almost 10/20% in new stores every year which takes to/3 years before they start hitting their top margin line. Still likes the company.

BUY

Has had some very good numbers of late. Has reasonable top line growth. Better and less risky than some of its competitors. Very solid company.

WEAK BUY

The seasonal period for this stock is from the end of September to the end of December. Technicals are at best neutral. Persistant growth of 15% which will probably not change. Consumer staple companies are being hit by high energy costs. Vulnerable to a slow down in revenues and earnings growth.

WATCH

Coming under a little bit of margin pressure. A little bit of slower growth then expected. Evaulation is a little bit high.

BUY

If you are looking at major chemicals, Dow Chemical (DOW-N) and Lyondell Chemical (LYO-N) would both be good. Lyondell is cheap, good dividend and has growth ahead of it.

BUY

A wonderful stock. For the past 5 years they have been building a ton of stores, and the new stores won't hit their profitability for 2/3 years. Now it's starting to come into play.

TOP PICK

Likes defensive names that produce good earnings growth. Benefit from having many locations. Expects extremely good growth.

DON'T BUY

Has grown rapidly over the last several years in terms of revenues, new stores. Analysis shows that cash flow return is not there.

TOP PICK

A stable grower. Double-digit growth is expected.

TOP PICK

Have been able to handle the competition well without a loss in margins. Have no debt. Expand new stores through cash flow.

DON'T BUY

Debt free. Growing very fast. A very expensive stock. Better off with a Canadian drug chain.

BUY

There's been weakness on the retail in the front of the store, but pharmaceuticals, prescriptioon growth is still there.

Showing 226 to 240 of 261 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Walgreen Boots Alliance (WBA)